AMGN
AMGEN INC
NASDAQ · Healthcare · Drug Manufacturers - General · US
$424.94
−1.75%Jul 30, 2026, 17:07 UTC
Amgen announced that the CHMP of the European Medicines Agency adopted a positive opinion supporting a broader use of Repatha before a first heart attack or stroke.
Source:Jul 24, 2026, 13:45 UTC
Amgen submitted new evidence to the FDA on July 23, 2026, to challenge the proposed withdrawal of its rare-disease drug Tavneos from the U.S. market.
Source:Jul 22, 2026, 16:30 UTC
Amgen filed a lawsuit against the Colorado Prescription Drug Affordability Review Board challenging the price cap on Enbrel.
Source:Jul 21, 2026, 15:10 UTC
Amgen reached a $74 million settlement of a shareholder lawsuit accusing it of hiding a $10.7 billion tax bill from the IRS.
Jul 20, 2026, 13:30 UTC
The Colorado Prescription Drug Affordability Review Board capped the price of Amgen's drug Enbrel at US$600 per weekly dose, effective January 1, 2027.
Jul 2, 2026, 23:54 UTC
Judge Daniel Domenico suspended Colorado's price cap on the prescription drug Enbrel, blocking it while a lawsuit by Amgen proceeds.
Jun 29, 2026, 20:46 UTC
The New England Journal of Medicine retracted an article on a pivotal clinical trial for Amgen's Tavneos drug after FDA findings of altered patient outcome data and unblinding of researchers.
Source:Jun 19, 2026, 08:07 UTC
Amgen India appointed Anjali Rao as executive director of human resources.
Source:Jun 15, 2026, 00:01 UTC
A Delaware jury found that Amgen and Teneobio willfully infringed Harbour BioMed's antibody discovery platform patents and awarded $20.2 million in damages.
Source:Jun 11, 2026, 23:28 UTC
Amgen hired a research firm to independently review Tavneos data after the U.S. health regulator proposed to withdraw the drug from the market.
Source:Jun 3, 2026, 13:43 UTC
The European Commission granted marketing authorization to Amgen's drug IMDYLLTRA for the treatment of advanced small cell lung cancer.
Source:
← PreviousPage 2